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Adequate amount of thyroid hormone is an essential requirement for normal 
development and maturity of bones in the early life as well as for the maintenance 
of the skeletal system (bone remodeling). Osteoporosis, one of the most common 
metabolic bone disorders, is strongly associated with hyperthyroidism (endogenous 
and exogenous), whereas association of the same disease with hypothyroidism is 
not quite established. Most of the data describing the association between osteo-
porosis and hyperthyroidism are collected among elderly population (especially 
postmenopausal women), and only a few studies in literature researched into osteo-
porosis and hyperthyroidism in <50 years of age; hence further studies are required 
in the younger population (including premenopausal women and younger males).
Keywords: bone remodeling, hyperthyroidism, hypothyroidism,  
postmenopausal women
1. Introduction
The skeletal system maintains a dynamic characteristic throughout its life by 
continuously undergoing bone modeling and bone remodeling processes [1–7]. 
Both bone modeling and remodeling processes include bone resorption mediated 
by osteoclasts and bone formation mediated by osteoblasts. Bone modeling is the 
predominant event during childhood, whereas in adults bone remodeling is the 
principal event [8]. In the case of bone modeling, both bone resorption and bone 
formation lead to major cur independently of one another at different sites of the 
skeletal system and lead to major change in the skeletal framework, whereas in the 
case of bone remodeling, both the processes of bone resorption and formation are 
closely related both in terms of time and site so that bone volume and density both 
remain more or less unchanged. The continuous process of bone remodeling repairs 
micro fractures, prevents formation of brittle bones, and balances calcium and 
phosphate homeostasis [6–8].
A number of systemic and local factors regulate the process of bone remodeling. 
Whenever the tightly coupled processes of bone resorption and bone formation in 
bone remodeling are disturbed, bone mineral diseases occur, excessive bone resorp-
tion leads to osteoporosis, and excessive bone formation leads to osteopetrosis [9].
Osteoblasts and osteoclasts are the two key players of bone remodeling; other 
cells involved in the process are osteocytes (derived from osteoblasts and acting 
as mechanosensor) and the bone lining cells [9]. The process of bone remodeling 
increases with aging; in both perimenopausal and menopausal women, the remod-
eling is faster than premenopausal women [9].
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There are a number of factors which are responsible for the development, 
maturation, and normal functioning of the skeletal system; these are genetic 
factors, maintenance of hormonal and metabolic harmony, adhering to balanced 
diet, exercise, etc. Any change in the abovementioned factors might lead to skeletal 
abnormality including restricted stature, deformity, osteoporosis, etc. [8, 10].
Osteoporosis leads to poor bone mass along with increased risk of fracture. 
Osteoporosis has emerged as a global healthcare problem with an estimated huge 
economic burden. Around 40% of women and 13–22% of men above 50 years will 
experience at least one episode of fracture (usually of spine, femur, or forearm) 
due to underlying osteoporosis in his or her lifetime [11]. Besides postmenopausal 
women and men above 50 years of age, the risk of secondary osteoporosis has 
increased in younger people as well [11].
Due to the increase in the number of patients with osteoporosis, all the second-
ary risk factors attributed to osteoporosis should be thoroughly investigated.
A number of factors are responsible for maintenance and development of the 
skeletal system; these are genetic factors, adequate hormonal and metabolic func-
tions, intake of balanced diet, and exercise (mechanical load) [11]. Any type of 
imbalance among the abovementioned factors might lead to severe consequences 
like short stature, bony deformities, and fractures. The final outcome depends upon 
age, type, severity, and duration of the underlying imbalance. Although not all of 
the abovementioned factors can be modified (like genetic factors), some of them 
can be modified [11, 12].
A rising number of new osteoporosis cases both in elderly and in young patients 
warrant the need for thorough investigations to identify all other secondary condi-
tions that might affect the disease negatively. Of all the secondary conditions, 
hormonal conditions are the most important ones that can lead to or aggravate 
osteoporosis [12]. Most commonly implicated endocrinological conditions are 
Cushing’s syndrome, hyperthyroidism, hypogonadism, acromegaly, diabetes mel-
litus, etc. Fortunately, majority of the negative effects of these hormonal disorders 
on the skeletal system can be modified [10–12].
1.1 Osteoblasts
Osteoblasts, the bone-forming cells in bone remodeling process, are derived 
from the pluripotent mesenchymal stem cells. Osteoblasts are also responsible for 
the secretion of Type I collagen which in turn is the major bone matrix protein. 
Besides the abovementioned functions, osteoblasts are also responsible for adequate 
mineralization of the new bone (osteoid). Bone mineralization occurs due to the 
locally released phosphates from the osteoblast-derived vesicles located within the 
osteoid. Extracellular calcium also contributes to the process of bone formation by 
the production of hydroxyapatite crystals. Maintenance of correct balance between 
bone matrix and minerals is the key factor for ensuring the right amount of rigidity 
and flexibility of the skeletal structure. Adult human cortical bones consist of 60% 
mineral, 20% organic material, and 20% water [8, 9].
1.2 Osteoclasts
These are micronucleated cells that are derived from the mononuclear mono-
cyte-macrophage cells. Osteoclasts, the only bone-resorbing cells, depend on two 
cytokines, colony-stimulating factor-1 or the macrophage colony-stimulating factor 
(CSF-1) and receptor activator of NF-kB ligand (RANKL), for production, expan-
sion, and survival. Osteoprotegerin (OPG) acts as a decoy receptor for RANKL and 
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inhibits the action of RANKL; hence the ration of RANKL to OPG determines the 
extent of osteoclast maturation and expansion [8, 9].
2. Physiology of thyroid hormones
The level of thyroid hormones in the circulation is controlled by the hypotha-
lamic-pituitary-thyroid axis (HPT axis) [13]. Thyrotropin-releasing hormone 
(TRH) is produced and secreted from the medial neurons of the paraventricular 
nucleus (PVN) of the hypothalamus. TRH in turn regulates both production and 
secretion of thyroid-stimulating hormone (TSH) from the anterior pituitary cells. 
Next, TSH through action on its receptor (TSHR) located on the follicular cells of 
the thyroid gland stimulates synthesis and secretion of the thyroid hormones. There 
are two types of thyroid hormones, 3,5,30,50-L-tetraiodothyronine (T4), the pro-
hormone, and 3,5,30-L-triiodothyronine (T3), the active hormone [14].
Thyroid hormones exert negative feedback effect on TRH and TSH and thus 
inhibit own synthesis and secretion.
Thus the HPT axis maintains a balanced relationship between the circulat-
ing thyroid hormones and their regulators like TSH and TRH. The set point for 
adequate functioning of the HPT axis is partly determined by genetic factors; there 
is an estimated genetic variation of 45–65% [13, 14].
2.1 Intracellular T3 supply
Circulating concentrations of both T4 and T3 along with target tissue uptake of 
the same and local activation or inactivation determine the intracellular supply of 
T3 (the active hormone). The thyroid gland secretes the pro-hormone T4 in larger 
proportions which is converted to the active form T3 in the liver and kidney through 
deiodination of T4 by type 1 iodothyronine deiodinase enzyme (DIO1). A major 
part (around 90%) of the circulating thyroid hormone remains bound to plasma 
proteins, and the concentration of free T3 (fT3) exceeds that of free T4 (fT4) by 
three to four times [13, 14].
There are specific membrane transporters associated with target tissue uptake of 
thyroid hormones; considered as monocarboxylate transporters (MCT8, MCT10), 
and organic acid transporter protein-1c1 (OATP1C1) [15]. Activity of T3 inside the 
cell is regulated by DIO2 and DIO3, as DIO2 converts T4 to T3 and DIO3 blocks the 
activation of T3 by producing reverse T3 [16].
Thyroid hormones mediate their actions through interaction with thyroid 
receptors (TRs). Unbound TRs bind with corepressor proteins and bind with 
thyroid response elements located at the promoter regions of the target genes and 
suppress transcription. Once thyroid hormone binds with its receptor, the receptor 
undergoes a conformational change with the unbinding of the corepressor proteins 
and facilitation of gene transcription following binding with the thyroid response 
elements at the target genes [14–16].
3. Thyroid hormone and the skeletal system
Action of T3 hormone on the skeletal system is rather complex and not completely 
understood. T3 mediates its action on the bones via direct and indirect pathways and 
affects the different phases of bone remodeling. T3 facilitates both osteoblastic (bone 
formation) and osteoclastic actions (bone resorption). T3 facilitates osteoblastic 
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activity by promoting production and differentiation of osteoblasts and also 
increases the expression of osteocalcin, collagen (Type 1), metalloproteins, alkaline 
phosphatase, etc. Similarly, T3 also facilitates differentiation of osteoclasts through 
increased expression of interleukin-6 and prostaglandins. It also exhibits synergistic 
action with hormones facilitating osteoclastic activity (like parathyroid hormone and 
vitamin D). Moreover, T3 promotes the expression of mRNA of RANKL, stimulates 
RANK, and thus facilitates osteoclast production [14–16].
Majority of the TRs expressed in the skeletal system (bone marrow, chondro-
cytes, osteoblasts, and osteoclasts) are TRβ1 and TRα1. Molecular studies have 
shown that the expression of TRα1 is far greater than that of TRβ1 in the skeletal 
system, indicating that T3-mediated action on the skeleton system is mostly carried 
out through TRα1 receptor [17]. There were no changes in the bone mass following 
the treatment of adult female rats with TRβ-selective agonist 3,5-dimethyl-4-(4-
hydroxy-3-isopropylbenzyl)phenoxy acetic acid (GC-1); however, the administra-
tion of supraphysiological dose of T3 led to significant loss of bone mass in the 
adult female rats [18]. These findings suggest that T3-mediated bone resorption 
occurs through TRα1 receptors [18]. Animal models with genetic modifications (for 
TRs) have led to better understanding of the actions of T3 on the skeletal systems. 
All these studies showed that mice with mutation of either both TRα1 and TRβ1 
or only TRα1 had delayed bone growth due to delayed ossification and decreased 
bone mineralization in early life, whereas increased bone mineralization in later 
years of life is similar to the effects of hypothyroidism in humans. However, mice 
with mutation of only TRβ1 receptors had skeletal phenotype similar to thyrotoxic 
patients characterized by increased mineralization and faster ossification during 
early life and decreased bone mineralization and poor bone mass in adult life [18].
3.1 Hyperthyroidism and osteoporosis
Thyroid hormones are known to a play key role in the linear growth of the 
skeletal system, and these hormones are essential to achieve the expected bone 
mass [19]. However, hyperthyroidism or thyrotoxicosis, a rather rare occurrence 
in children, if present, leads to accelerated ossification (both intramembranous 
and endochondral) and rapid linear growth [17]. This accelerated increase in bone 
age often results in early epiphyseal closure and short stature. In younger children 
severe degree of thyrotoxicosis might lead to premature closure of cranial sutures 
and craniosynostosis (impaired growth of brain and skull) with neurological 
complications [17, 20]. Sometimes severe untreated thyrotoxicosis in mother might 
lead to craniosynostosis in the growing fetus [20].
In adults hyperthyroidism shorten the bone turnover and poor bone mineral-
ization [11, 17]. Finally there is loss of bone mineral density by around 10–20% 
especially in the cortical bones [11]. The increased concentration of circulating 
thyroid hormones causes significant shortening of bone remodeling cycle by about 
50%. Normally the average bone remodeling cycle lasts for 200 days; however, with 
hyperthyroidism it is shortened to an average of 113 days [11, 21, 22]. Hence the bal-
ance between bone resorption and bone formation is disturbed; the bone formation 
phase is severely compromised (the duration is decreased by 2/3) and is ultimately 
responsible for poor mineralization (loss of about 10% of mineralization of bone 
per cycle) [11]. All these effects lead to increased risk of osteoporosis and increased 
chance of fracture.
Another contributory factor for increased risk of osteoporosis in patients of 
hyperthyroidism is that there is increased circulatory concentration of IL-6 in these 
patients; IL-6 is known to be an activator for osteoclast production and facilitates 
action of parathyroid hormone in bones [11, 23]. Hyperparathyroidism is also 
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known to cause negative calcium balance due to hypercalcemia and hypercalciuria. 
Negative calcium balance further increases the risk of osteoporosis in these already 
vulnerable patients.
Many researchers since Von Recklinghausen have been conducting researches on 
the effects of thyroid dysfunction on bones. Svare A and his colleagues conducted 
a cross-sectional study to assess the relationship between BMD of forearm and 
TSH level in Norwegian female population (HUNT2 Study) [24]. They found that 
women with lower TSH (<0.5 mU/L) had lower forearm BMD than the reference 
category. Similarly, the prevalence of osteoporosis was found to be higher in women 
with osteoporosis than those without any history of thyroid disorder.
Again, the occurrence of osteoporosis secondary to hyperthyroidism (thyrotoxi-
cosis) is more common in postmenopausal women than premenopausal women. 
Ercolano MA and his colleagues conducted a non-interventional and cross-sectional 
study on euthyroid (who had euthyroid for the past 6 months) pre- and postmeno-
pausal women with past history of hyperthyroidism due to Graves’ disease [25]. It 
was found that BMD was significantly affected only in the postmenopausal group 
of women who remained euthyroid for the past 6 months and have a past history of 
Graves’ disease. Again, Tuchendler and Bolanowski conducted a study on premeno-
pausal women with hyper- and hypothyroidism to assess the effects of thyroid 
dysfunction on osteoporosis [26]. They found that only hyperthyroidism and not 
hypothyroidism can significantly affect BMD (measured at the femoral neck), and 
following the treatment for 12 months, a statistically significant increase in BMD 
in femoral neck was observed in premenopausal women with hyperthyroidism and 
not hypothyroidism.
Similar study was conducted in men by El Hadidy and his colleagues [27]. The 
study included males between 23 and 65 years with hyperthyroidism (Graves’ 
disease or toxic nodular goiter). The researchers found that the men with hyper-
thyroidism had a significant fall in BMD compared to age-matched healthy men 
without any thyroid dysfunction. Besides this, the severity and the duration of 
hyperthyroidism were directly related to the increase in bone turnover markers and 
the degree of bone loss.
Similar study was conducted by Ale and her colleagues [28]. This cross-sectional 
study included females and males between 22 and 50 years. It was found that BMD 
measured in hyperthyroidism was significantly reduced compared to age- and sex-
matched healthy controls. Osteoporosis was documented in hyperthyroidism but 
not in the controls.
Again a systematic review and meta-analysis of cohort studies by Yang and his 
fellow researchers documented that although both subclinical hypo- and hyperthy-
roidism are associated with increased risk of fracture, only subclinical hyperthy-
roidism and not subclinical hypothyroidism showed significant association with 
low BMD (osteoporosis) [29].
3.1.1 Subclinical hyperthyroidism and osteoporosis
Although medical data describing the relation between subclinical hyperthy-
roidism and osteoporosis is not much, still there are studies which have explored the 
relationship between the two. Segna and his colleagues published a study exploring 
the association between subclinical hyperthyroidism and osteoporosis [30]. They 
included all the prospective cohort studies (published between 1946 and 2016) in 
the electronic database (MEDLINE/EMBASE) which provided baseline thyroid 
hormone status and repeated measurements of BMD. The study found that in adult 
patients subclinical hyperthyroidism is significantly associated with bone loss in the 
femoral neck region leading to increased risk of osteoporosis and fracture.
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However, some earlier studies as the one conducted by Földes and his colleagues 
have described that although in premenopausal women with subclinical hyper-
thyroidism BMD in femoral neck, lumbar spine, and in the midshaft of radius did 
not decrease significantly, the same condition might contribute to osteoporosis in 
postmenopausal women especially in the cortical bones [31]. Another study pub-
lished by Lee and his fellow researchers revealed that both subclinical hypo- and 
hyperthyroidism are associated with increased risk of hip fracture in elderly men; 
however, no such association was found with women [32].
Vadiveloo and his colleagues published a retrospective study exploring the 
long-term consequences of subclinical hyperthyroidism (TEARS study) [33]. The 
researchers identified suitable patients using population record linkage technology 
retrospectively between January 1, 1993 and December 31, 2009. They found that 
patients with endogenous subclinical hyperthyroidism showed an increased risk of 
osteoporosis-related fracture (hazard ratio being 1.25) when compared with refer-
ence population; however, once these patients developed overt hyperthyroidism or 
euthyroidism and are excluded from the study, this association is lost.
Again, Saler and his colleagues described in their study that in contrast to exog-
enous subclinical hyperthyroidism, endogenous subclinical hyperthyroidism does 
not compromise BMD in premenopausal women and therefore do not pose a risk for 
either osteoporosis or osteopenia [34]. However, Tauchmanovà and her colleagues 
found that BMD of the femoral neck was significantly decreased in both pre- and 
postmenopausal women with endogenous subclinical hyperthyroidism (greater in 
in postmenopausal women). Study of lumbar spine BMD revealed bone loss only 
in postmenopausal women. Similar findings were documented by Rosario and his 
colleagues [35].
Thus it can be suggested that the threat of osteoporotic fracture is greater with 
exogenous subclinical hyperthyroidism especially in postmenopausal women.
3.2 Overt hypothyroidism and osteoporosis
Hypothyroidism is a rather common condition in children and is characterized 
by delay in the development of the skeletal system, poor growth, and impaired and 
early endochondral ossification leading to short stature and defective bone matu-
ration. Patients often present with patent skull sutures (delay in closure of skull 
fontanelles) and typical facial characteristics like flattened nasal bridge and broad 
face due to defective ossification.
In severe cases postnatal growth can be completely arrested, impaired with 
skeletal growth characterized by epiphyseal dysgenesis, dislocation of hip joints, 
scoliosis, persistent patency of the fontanelles, and delay in eruption of tooth. 
Thyroid hormone replacement therapy in these children leads to “catch-up” growth 
with achievement of skeletal maturity and improved bone mineralization. Finally 
in most of the children, normal adult height and bone mineral density are achieved. 
However, in severely affected children and those with significant delay in receiv-
ing thyroid hormone replacement therapy, expected adult stature might not be 
achieved.
Several studies were conducted in adults to understand the effect of thyroid hor-
mone disorder on adult skeletal system [11]. But several factors like heterogeneity of 
the study population, the presence of different confounding factors, and different 
end points for different studies have led to the uniform interpretation of the results 
obtained from these studies.
Earlier histomorphometric studies have shown that hypothyroidism in adults led 
to slow bone turnover with both poor bone formation by osteoblasts and decreased 
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bone resorption by osteoclasts. Also increase in the bone remodeling time led to 
prolonged secondary mineralization of the bone without any change in the existing 
bone volume. However, all the abovementioned changes are very slow to occur, and 
there are hardly any clinical data to suggest these findings in adult patients [11].
Although the exact mechanism is not known, hypothyroidism is considered to 
increase the risk of fracture. Vestergaard and his fellow researchers documented in 
their study that following diagnosis of primary idiopathic hypothyroidism, the risk 
of fracture (in forearm) was significantly increased in patients above 50 years [36].
However, González-Rodríguez and his colleagues while assessing the prevalence 
of thyroid dysfunction in adult female population, from the data collected in the 
Latin American Vertebral Osteoporosis Study (LAVOS), documented that although 
there was a high prevalence of hypothyroidism in these females, no association 
between loss of bone mineral density and hypothyroidism was found [37]. They 
also found that there was no association between fractures (vertebral or nonverte-
bral) and hypothyroidism.
3.3  Prolonged treatment with TSH suppressive therapy with supraphysiological 
dose of levothyroxine (synthetic form of T4) and osteoporosis
Supraphysiological doses of levothyroxine are prescribed in patients of thyroid 
cancer following surgery and radioactive iodine therapy. Prolonged exposure to 
levothyroxine therapy might increase the risk of secondary osteoporosis [11].
Heemstra and his colleagues described that, although long-term thyroxine 
therapy increased the risk of poor BMD and thus osteoporosis, it was not seen in 
men and in premenopausal women [38].
In the year 2018, Mazziotti and his colleagues published a cross-sectional study 
conducted mainly on postmenopausal women (178 women were postmenopausal 
out of 179 of the study participants) [39]. These women underwent thyroidectomy 
for differentiated thyroid carcinoma and were receiving levothyroxine therapy. 
Radiological vertebral fractures (VF) are considered as an early indicator of bone 
fragility. The researchers found that the prevalence of VF was significantly greater 
in patients with TSH level <1.0 mU/L, duration of levothyroxine therapy, and 
densiometric diagnosis of osteoporosis.
Thus it can be suggested that the risk of osteoporosis increases with suppression 
of TSH therapy.
4. Conclusion
Osteoporosis is considered to be one of the most common skeletal disorders 
affecting both elderly and young patients. Besides the few primary causes (aging 
and menopause), in most of the cases, osteoporosis occurs due to underly-
ing secondary causes. Common secondary risk factors for osteoporosis include 
hormonal disorders like Cushing’s disease, hyperthyroidism, diabetes mellitus, 
hypogonadism, etc. Several studies have established that hyperthyroidism both 
endogenous (due to Graves’ disease or toxic nodular goiter) and exogenous (due to 
prolonged levothyroxine therapy especially in patients with differentiated thyroid 
cancer) increases the risk of osteoporosis profoundly in postmenopausal women. 
Even subclinical hyperthyroidism especially the exogenous ones might lower BMD 
and increases the risk of osteoporosis, more commonly in postmenopausal women. 
Hypothyroidism, on the other hand, although responsible for an array of bone 
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Most of the studies, exploring the association between hyperthyroidism (exog-
enous or endogenous) and osteoporosis, are usually conducted among elderly 
population (postmenopausal women and elderly men). Hence further studies are 
to be conducted to explore the association of hyperthyroidism and osteoporosis in 
younger population (premenopausal women and younger males).
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